Received Nov 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 99H9A | — |
Additional doses of FluLaval given; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 33-year-old female patient who received Flu Seasonal TIV Quebec (FluLaval 2024-2025 season) (batch number 99H9A, expiry date 30-JUN-2026) for prophylaxis. Concomitant products included Influenza vaccine inact split 3v (Flulaval). On 30-OCT-2025, the patient received the 2nd dose of FluLaval 2024-2025 season. On 30-OCT-2025, an unknown time after receiving FluLaval 2024-2025 season, the patient experienced extra dose administered (Verbatim: Additional doses of FluLaval given). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 29-OCT-2025 The clinical manager reported that a patient accidentally received 2 doses of Flulaval within one month. The vaccine administration facility was the same as primary reporter.